摘要
为评价532 nm激光联合后Tenon囊下注射曲安奈德治疗糖尿病视网膜病变(DR)的治疗效果,针对47例78眼DR患者治疗,并在1周、2周、1月、3月、6月检查视力、眼压、眼底,1月检查FFA及OCT,显示视力提高29眼(37.2%),视力下降7眼(9.0%),视力稳定42眼(53.8%);眼底及FFA复查显示无灌注区全部消退46眼(59.0%),部分消退27眼(34.6%);OCT复查黄斑区厚度降低;无严重并发症发生。结果表明532 nm激光联合后Tenon囊下注射曲安奈德治疗DR安全、经济、有效,仍不失为DR治疗的重要手段和选择,适合基层医院和经济不发达地区开展。
Aiming to evaluate the therapeutic effect of 532 nm laser combined with posterior sub-Tenon injection of triamcinolone acetonide in treating diabetic retinopathy,47 patients(78 eyes)with diabetic retinopathy were treated.The visual acuity,intraocular pressure,fundus were performed at 1 week,2 weeks,1 month,3 months,and 6 months.The FFA examination and OCT examination were performed for 1 month,which showed that visual acuity was improved in 29 eyes(37.2%),visual acuity decreased in 7 eyes(9.0%),and visual acuity was stabilized in 42 eyes(53.8%).The fundus and FFA review showed that there were 46 eyes(59.0%)in no-perfusion area were all resolved,part resolved 27 eyes(34.6%).The thickness of OCT reviewed macular area were reduced and without serious complications occurred.The results show that it is safe,economical and effective,and is still an important means and choice for DR treatment with 532 nm laser combined with posterior sub-Tenon injection of triamcinolone acetonide,and is suitable for primary hospitals and underdeveloped area areas.
作者
吴小军
方廷兵
王增智
王艳丽
WU Xiaojun;FANG Tingbing;WANG Zhengzhi;WANG Yanli(Union Shenzhen Hospital,Huazhong University of Science and Technology,Shenzhen 51S000.China)
出处
《激光杂志》
北大核心
2020年第9期225-228,共4页
Laser Journal
基金
深圳南山区科技计划项目(No.2019064)。